AtriCure (NASDAQ:ATRC) Insider Salvatore Privitera Sells 8,404 Shares of Company Stock

AtriCure, Inc. (NASDAQ:ATRC) insider Salvatore Privitera sold 8,404 shares of AtriCure stock in a transaction dated Wednesday, November 4th. The shares were sold at an average price of $65.00, for a total transaction of $546,260.00. Following the completion of the sale, the insider directly owned 134,341 shares in the company, valued at approximately $8,732,165. The trade was a 5.89% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Salvatore Privitera also recently made the following trade(s):

• On Wednesday, September 23rd, Salvatore Privitera sold 4,519 shares of AtriCure stock. The stock was sold at an average price of $60.00, for a total transaction of $271,140.00.
• On Tuesday, September 8th, Salvatore Privitera sold 3,657 shares of AtriCure stock. The shares were sold at an average price of $55.00, for a total transaction of $201,135.00.
• On Wednesday, September 2nd, Salvatore Privitera sold 7,763 shares of AtriCure stock. The shares were sold at an average price of $52.50, for a total value of $407,557.50.

AtriCure Stock Performance

NASDAQ ATRC traded down $4.27 on Thursday, hitting $61.26. 978,420 shares of the company’s stock were exchanged, compared to its average volume of 875,183. The firm has a market cap of $3.12 billion, a price-to-earnings ratio of 204.21 and a beta of 1.23. The firm’s 50-day moving average price is $56.36 and its two-hundred day moving average price is $38.52. AtriCure, Inc. has a fifty-two week low of $25.36 and a fifty-two week high of $66.02. The company has a debt-to-equity ratio of 0.14, a current ratio of 4.22 and a quick ratio of 3.19.

AtriCure (NASDAQ:ATRC) last posted its quarterly earnings results on Tuesday, November 3rd. The medical device company reported $0.17 EPS for the quarter, beating the consensus estimate of ($0.06) by $0.23. AtriCure had a return on equity of 4.08% and a net margin of 2.52%. The business had revenue of $154.45 million during the quarter, compared to analysts’ expectations of $151.05 million. On average, research analysts expect that AtriCure, Inc. will post 0.29 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the business. Harbor Investment Advisory LLC acquired a new position in shares of AtriCure during the 2nd quarter worth approximately $40,000. Allworth Financial LP acquired a new position in shares of AtriCure in the second quarter worth $43,000. Integrated Wealth Concepts LLC acquired a new position in shares of AtriCure in the second quarter worth $46,000. Fifth Third Bancorp acquired a new stake in shares of AtriCure during the first quarter valued at $51,000. Finally, Global Retirement Partners LLC acquired a new stake in shares of AtriCure during the second quarter valued at $52,000. 99.11% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

ATRC has been the topic of a number of recent analyst reports. Citigroup reaffirmed a “market outperform” rating on shares of AtriCure in a research note on Wednesday, October 21st. Needham & Company LLC upped their target price on shares of AtriCure from $64.00 to $70.00 and gave the stock a “buy” rating in a research report on Wednesday. Weiss Ratings raised shares of AtriCure from a “hold (c-)” rating to a “hold (c)” rating in a report on Thursday, October 8th. Freedom Capital lowered AtriCure from a “strong-buy” rating to a “hold” rating in a research note on Friday, October 2nd. Finally, JPMorgan Chase & Co. upped their price target on AtriCure from $36.00 to $62.00 and gave the stock a “neutral” rating in a report on Wednesday. Six research analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $61.80.

Key AtriCure News

Here are the key news stories impacting AtriCure this week:

• Positive Sentiment: Third-quarter adjusted earnings were $0.17 per share, ahead of estimates, and revenue of $154.45 million topped forecasts of $151.05 million. AtriCure beats Q3 earnings and revenue estimates
• Positive Sentiment: AtriCure raised its 2026 revenue outlook to $606 million–$610 million and projected adjusted EBITDA of $91 million–$94 million. It also aims to complete BoxX-NoAF enrollment by year-end. 2026 EBITDA outlook and enrollment target
• Positive Sentiment: Analysts raised targets following the results: Piper Sandler and Needham lifted theirs to $70, while Canaccord raised its target to $67 and maintained a Buy rating. Analysts raise forecasts after Q3 results
• Neutral Sentiment: JPMorgan raised its target to $62 but kept a Neutral rating, signaling more limited expected upside from its assessment. Analyst forecast updates
• Negative Sentiment: Despite the upbeat results and guidance, investors may be weighing whether ATRC is fully valued after its substantial run-up. Its elevated valuation could make the shares vulnerable to profit-taking and help explain the pullback. Is AtriCure fully valued after strong results and raised guidance?

AtriCure Company Profile

AtriCure, Inc is a medical device company that develops and sells products for the surgical treatment of atrial fibrillation (AFib) and related conditions. Its technologies are designed to support cardiac surgeons and electrophysiologists performing tissue ablation, left atrial appendage management and other procedures intended to restore or maintain normal heart rhythm.

The company’s product portfolio includes the AtriClip device, which is used to exclude the left atrial appendage, along with surgical ablation systems such as the Isolator Synergy clamps and cryoablation products.